title: Review of hemophagocytic lymphohistiocytosis (HLH) in children with focus on Japanese experiences.
abstract: Hemophagocytic lymphohistiocytosis (HLH) is characterized by fever and hepatosplenomegaly associated with pancytopenia, hypertriglyceridemia and hypofibrinogenemia. Increased levels of cytokines and impaired natural killer activity are biological markers of HLH. HLH can be classified into two distinct forms, including primary HLH, also referred to as familial hemophagocytic lymphohistiocytosis (FHL), and secondary HLH. Although FHL is an autosomal recessive disorder typically occurring in infancy, it is important to clarify that the disease may also occur in older patients. It is now considered that FHL is a disorder of T-cell function; moreover, clonal proliferation of T lymphocytes is observed in a few FHL patients, and cytotoxicity of these T lymphocytes for target cells is usually impaired. In 1999, perforin gene (PRF1) mutation was identified as a cause of 20-30% of FHL (FHL2) cases. In Japan, two specific mutations of PRF1 were also detected. Furthermore, in 2003, MUNC13-4 mutations were identified in some non-FHL2 patients (FHL3). Identification of other genes responsible for remaining cases is a major concern. Hematopoietic stem cell transplantation (HSCT) has been established as the only accepted curative therapy for FHL. Thus, appropriate diagnosis and prompt treatment with HSCT are necessary for FHL patients. Genetic analysis for PRF1 and MUNC13-4 and functional assay of cytotoxic T lymphocytes are recommended to be performed in each patient. In those patients displaying impaired cytotoxic function but lacking genetic defects, samples should be employed for identification of unknown genes. In the near future, an entire pathogenesis should be clarified in order to establish appropriate therapies including immunotherapy, HSCT and gene therapy.
authors.affiliation: Department of Pediatrics, Faculty of Medicine, Saga University, 5-1-1 Nabeshima, Saga 849-8501, Japan. ishiei@med.saga-u.ac.jp
authors.forename: Eiichi
authors.initials: E
authors.lastname: Ishii
authors.forename: Shouichi
authors.initials: S
authors.lastname: Ohga
authors.forename: Shinsaku
authors.initials: S
authors.lastname: Imashuku
authors.forename: Nobuhiro
authors.initials: N
authors.lastname: Kimura
authors.forename: Ikuyo
authors.initials: I
authors.lastname: Ueda
authors.forename: Akira
authors.initials: A
authors.lastname: Morimoto
authors.forename: Ken
authors.initials: K
authors.lastname: Yamamoto
authors.forename: Masaki
authors.initials: M
authors.lastname: Yasukawa
mesh_terms: D002648:Child; D015616:Histiocytosis, Non-Langerhans-Cell / Q000453:epidemiology / Q000209:etiology* / Q000235:genetics / Q000276:immunology; D006801:Humans; D007564:Japan / Q000453:epidemiology; D008562:Membrane Glycoproteins / Q000235:genetics; D009154:Mutation; D009419:Nerve Tissue Proteins / Q000235:genetics; D054353:Perforin; D052899:Pore Forming Cytotoxic Proteins; D013601:T-Lymphocytes / Q000276:immunology / Q000473:pathology
chemical_list: D008562:Membrane Glycoproteins; D009419:Nerve Tissue Proteins; D052899:Pore Forming Cytotoxic Proteins; C485548:UNC13B protein, human; D054353:Perforin